1. Home
  2. FAMI vs GNPX Comparison

FAMI vs GNPX Comparison

Compare FAMI & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmmi Inc.

FAMI

Farmmi Inc.

N/A

Current Price

$1.32

Market Cap

7.8M

ML Signal

N/A

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$1.95

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FAMI
GNPX
Founded
2015
2009
Country
China
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
6.4M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
FAMI
GNPX
Price
$1.32
$1.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.9K
830.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
76.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.14
52 Week High
$2.22
$12.97

Technical Indicators

Market Signals
Indicator
FAMI
GNPX
Relative Strength Index (RSI) 48.83 44.42
Support Level $1.30 $1.90
Resistance Level $1.36 $2.51
Average True Range (ATR) 0.07 0.21
MACD 0.01 0.01
Stochastic Oscillator 47.37 27.63

Price Performance

Historical Comparison
FAMI
GNPX

About FAMI Farmmi Inc.

Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe, and the Middle East under the Forasen and Farmmi brands.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: